in Nice, a unique machine in the world makes it possible to sterilize tumors linked to colorectal cancer

in Nice, a unique machine in the world makes it possible to sterilize tumors linked to colorectal cancer

At the Antoine Lacassagne Center, a machine dramatically regresses colorectal cancer tumors. She is able to “bombard” tumors with X-rays with extreme precision, until they shrink by half, in a single session.

This is a weapon that could well tip the war against cancer. The management of this type of disease is constantly evolving, and it is in Nice, at the Antoine Lacassagne Center, that cutting-edge technologies are helping to cure patients.

In France, colorectal cancer is detected, according to figures provided by Public Health France, in 43,336 people each year, and 17,117 deaths are linked to it annually.

A national screening program is offered for both men and women over 50 years old.

It is on the treatment side that these patients will be able to turn to hope for a rapid and effective cure.

“I did the first radio session, and then the teacher told me ‘it’s extraordinary, it has been reduced by half’. For Abbas Faraht, who was diagnosed at the beginning of the year with colorectal cancer, it is a real – and pleasant – surprise to have been able to see the benefits of this treatment on his disease, which he believed to be fatal.

Already, the word cancerous tumour, you know it’s dangerous, there are psychological issues all of a sudden because it’s something that can be fatal if not detected in time.

Abbas Faraht

Patient with colorectal cancer

This is the device that is in the brachytherapy application room is unique in the world. It sends a massive dose of X-rays to cancerous tissue, sparing surrounding healthy tissue, and on a very small area.

A European study called OPERA (for Organ Preservation in Early Rectal Adenocarcinoma or Organ Preservation in Early Rectal Adenocarcinoma in French)

“The scientific proof has just been provided by this famous randomized trial […] and we have shown that when we only did normal rays, we had 60% success, and that we increased to 90% by adding 3 sessions of the Papillon device.” concedes Professor Jean-Pierre Gérard, from the Center Antoine Lacassagne.

These results were presented at the ASCO congress (the American association of oncology), in Chicago in the United States, this June 4, 2022. They demonstrate that by supplementing external radiotherapy with contact radiotherapy, this cure rate is effective on tumors of less than 3 centimeters, with only these three additive sessions lasting 5 minutes each.

The Papillon 50, which bears the name of the French professor who developed this tool, technology brings other benefits:this avoids surgery with potential functional consequences, […] and this is particularly interesting in patients who are elderly, and for whom surgery would expose them to significant anesthetic and surgical risks” details doctor Cyrielle Scouarnec.

All patients who were treated in the OPERA study have since been in remission.

Leave a Comment

Your email address will not be published.